14th Apr 2016 08:06
LONDON (Alliance News) - Vernalis PLC said Thursday it has completed its multiple-dose comparative bioavailability study of cough-cold treatment CCP-07, and a new drug application for CCP-07 remains on track for 2016.
CCP-07 is in development for Vernalis by Tris Pharma Inc, and is the second of up to six treatments in development under this agreement. The first, Tuzistra XR, was approved by the US Food and Drug Administration in April, whilst the third, CCP-08, recently completed a single-dose comparative bioavailability study.
"We are delighted with the successful completion of CCP-07 pivotal bioavailability studies and look forward to further news flow from this programme in 2016," said Chief Executive Officer Ian Garland in a statement.
Shares in Vernalis were up 2.0% at 52.50 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC